CC-223
Sponsors
Celgene
Conditions
Diffuse Large B-Cell LymphomaGlioblastoma MultiformeHealthy VolunteersHepatocellular CarcinomaHormone Receptor-Positive Breast CancerLymphoma, Large B-Cell, DiffuseMultiple MyelomaNeuroendocrine Tumors of Non-Pancreatic Origin
Phase 1
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
CompletedNCT01177397
Start: 2010-07-20End: 2016-12-09Updated: 2022-12-13
A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects
CompletedNCT01611467
Start: 2012-06-01End: 2012-07-01Updated: 2019-11-12
CC-223 and Ketoconazole Drug-Drug Interaction Study
CompletedNCT01896323
Start: 2013-07-01End: 2013-08-01Updated: 2019-11-12
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma
TerminatedNCT02031419
Start: 2013-12-18End: 2023-12-12Updated: 2024-01-18